J&J's Yondelis may finally be heading for approval; Brickell raises $10M;

@FierceBiotech: Cornell team engineers a probiotic GLP-1 therapy for diabetes. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Sanofi, Roche and Lilly help bankroll a $20M round for Parkinson's player LTI. Report | Follow @JohnCFierce

@DamianFierce: Biotech companies just don't close anymore. Report | Follow @DamianFierce

> Johnson & Johnson's ($JNJ) long-delayed cancer drug Yondelis secured the FDA's priority review designation, promising a 6-month review instead of the standard 10. News

> Dermatology drug developer Brickell Biotech raised $10 million in Series C cash to support its mid-stage treatment for excessive sweating. More

> Sanofi ($SNY) and partner MannKind ($MNKD) have launched Afrezza, an inhaled insulin that faced years of regulatory setbacks before picking up FDA approval last year. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic partners with LHC to provide at-home, post-acute care patient monitoring services. Article | Follow @FierceMedDev

@VarunSaxena2: FDA clears 3-D printed device for minimally invasive foot surgery. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists renewing research for psychedelics as a treatment for anxiety and depression. More from The New Yorker | Follow @EmilyWFierce

> Feds set reimbursement targets, increasing government payments' impact on device world, M&A. More

> FTC probes Wright, Tornier merger again, may push deal close into the second half. Article

Pharma News

@FiercePharma: ICYMI from FierceAnimalHealth: IDEXX raises 2015 sales forecast on predicted demand for new lab tests. Article | Follow @FiercePharma

@EricPFierce: FDA issues warning letter to a second Apotex plant in India. Data manipulation alleged again. Letter | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire's ADHD star Vyvanse scores FDA's first binge eating approval. Article | Follow @CarlyHFierce

> It's put up or shut up time for Sanofi and MannKind as Afrezza hits the market. More

> FDA study spanks drugmakers for poor adverse events reporting. Story

Biotech Research News

> Cleveland Clinic team posts a big target for CKD drug developers. Story

> Dartmouth team tags HER4 as a key culprit for HER2 drug resistance. More

> Johns Hopkins technique opens a new window on brain disorders. Item

> Investigators zero in on an enzyme linked to BRCA1/2 cancer mutations. Story

> Cardiac study points to new treatment to guard against arrhythmias. Article

Pharma Manufacturing News

> Vertellus completes $200M deal for Dow plant that makes sodium borohydride. Story

> Sanofi ups diabetes game in India through hospital clinics, local production. Article

> Biogen Idec expands North Carolina manufacturing operations. More

> Emerging market demand saves Irish Lipitor plant from closing. Story

> Dr. Reddy's mulling facility shift to avoid losing out on Nexium generic. Report

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.